Epidemiology Study - Overview

Helicobacter Pylori Infection Study Objective:

To determine the prevalence and incidence of Helicobacter Pylori Infection among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Helicobacter Pylori Infection within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Moreover, the report is having geographic coverage including North America, Europe and rest of the world however customisation can be made in the geographic coverage.

Helicobacter Pylori Infection Study USP:

• This epidemiological study on Helicobacter Pylori Infection stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.
• By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Helicobacter Pylori Infection related health problems.
• Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of Helicobacter Pylori Infection but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Helicobacter Pylori Infection cases.

Helicobacter Pylori Infection related Study Overview:

The study Defines Helicobacter Pylori Infection as an advanced form of disease. The significance of studying Helicobacter Pylori Infection epidemiology is due to its increasing prevalence in different age populations.

Helicobacter Pylori Infection Study Design:

Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying Helicobacter Pylori Infection cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).

Helicobacter Pylori Infection Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between Helicobacter Pylori Infection and potential risk factors (e.g., age, smoking, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.

Helicobacter Pylori Infection study summary:

Helicobacter Pylori Infection study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Helicobacter Pylori Infection worldwide.

Helicobacter Pylori Infection Disease overview:

Helicobacter pylori (H. pylori) is a type of bacteria that can infect the stomach lining. This infection may lead to inflammation (gastritis) or the development of ulcers in the stomach or the upper part of the small intestine (duodenum). In some individuals, especially if left untreated, H. pylori can increase the risk of developing stomach cancer.

It is the most common human bacterial infection affecting 4.4 billion people, accounting about 50% of the world population. According to one of the study reported in AGA Journals, Global prevalence of Helicobacter Pylori Between 2015 and 2022, the estimated global prevalence of Helicobacter pylori infection was approximately 43.9% among adults and 35.1% among children and adolescents. Developing countries had prevalence rates in range of 80 to 95% and 30 to 50 % prevalence in developed countries.

From 2015 to 2022, H. pylori infection rates varied across countries. Among adults, the lowest prevalence was observed in Finland (9.1%), New Zealand (9.2%), Croatia (13.3%), Indonesia (14.4%), and Hong Kong (15.0%), and the highest rates were reported in Jordan (88.6%), Guatemala (86.6%), Ecuador (85.7%), Nicaragua (83.3%), and Colombia (83.1%). In children and adolescents, the lowest infection rates were found in the Czech Republic (5.2%), South Korea (5.9%), the Netherlands (9.3%), Taiwan (11.0%), and Hong Kong (12.8%), furthermore, the highest rates in this age group were seen in India (80.0%), Bhutan (71.1%), Yemen (64.7%), Bangladesh (59.6%), and Chile (55.9%).

Various treatment options available in market include Antibiotic Therapy, Proton Pump Inhibitors, Bismuth Compounds, Combination Therapy. Key market players manufacturing the therapeutics for the treatment of H. Pylori infection are as follows Pfizer, BristolMyers Squibb, Johnson and Johnson, AstraZeneca, Alexion Pharmaceuticals, Otsuka Pharmaceutical, Hikma Pharmaceuticals, Takeda Pharmaceutical, AbbVie, GSK, Merck and Co, Valeant Pharmaceuticals, Novartis, Sanofi.

October 2023, the U.S. FDA approved Phathom Pharmaceuticals’ reformulated vonoprazan tablets for use in VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin). These treatments are designed for the eradication of Helicobacter pylori (H. pylori) infection in adults. The approval follows a Prior Approval Supplement (PAS) submission and is based on data from the PHALCON-HP Phase 3 trial, the largest U.S. registrational study for H. pylori to date.

The VOQUEZNA regimens combine antibiotics with vonoprazan, a novel potassium-competitive acid blocker (PCAB)—the first new class of acid suppressant approved in the U.S. in over 30 years. These new formulations aim to improve treatment outcomes by addressing challenges such as antibiotic resistance, inadequate acid suppression, and complex regimens.

Helicobacter Pylori Infection Demographic and Environmental Risk Factors:

Age and Sex: Prevalence increases with age, about 20% of people under 30 are infected, 50% in those over 60. According to study published in PubMed Central, males are showing higher prevalence of H. pylori infection in both children and adults compared to females. Some other studies show similar incidence rates between men and women.

Ethnicity: According to one of the study reported in Journal of Infectious Diseases of Oxford Academic, The prevalence of H. pylori infection shows significant variation across ethnic groups. It is notably higher among non-Hispanic Blacks (52.7%) and Mexican Americans (61.6%) compared to non-Hispanic Whites (26.2%). Another report published by The University of Arizona, In the U.S., H. pylori infection is more common among Hispanics (60%) and African Americans (54%) compared to Whites (20%).

Risk Factors causing Helicobacter Pylori Infection: Several environmental and social conditions can increase the likelihood of Helicobacter pylori infection, particularly during childhood. These include:

• Residing in densely populated households, which facilitates the spread of infection.
• Living in environments with limited access to clean and safe drinking water.
• Growing up in regions with lower socioeconomic development or in developing countries.
• Sharing a home with individuals already infected with H. pylori, which raises the risk of transmission.

Helicobacter Pylori Infection Market Scope:

Drivers: The global incidence of Helicobacter pylori infections is on the rise, and this increase is one of the most significant drivers of growth within the Helicobacter pylori Infections Treatment Market Industry. As more individuals are diagnosed with these infections, the demand for effective treatment options has surged. The bacterium is known to be associated with numerous gastrointestinal disorders, including gastritis, peptic ulcers, and an increased risk of gastric cancer. This alarming relationship draws attention to H. pylori as a major public health concern. Increased awareness among healthcare professionals and patients regarding the adverse effects of untreated infections has prompted more people to seek diagnostic testing and effective therapies.

Innovative therapeutic strategies and advancements in pharmacological treatments are fueling the growth of the Helicobacter pylori Infections Treatment Market Industry. Breakthroughs in antibiotic therapies, proton pump inhibitors, and novel drug formulations enhance the efficacy of treatment regimens. This evolution helps to address antibiotic resistance issues that have emerged over time, ensuring more effective eradication rates and better patient adherence.

Restraints: limitations of diagnostic test, cost constraints, regulatory approval hurdles delaying the product launch, drug resistance are some of the factors which can hamper the growth of the market involved in manufacturing the therapeutics for the treatment of Helicobacter Pylori infection.